We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Nutex Health Inc. (NASDAQ:NUTX) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it. Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks. Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers. Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified 15 Energy Stocks that are Up the Most in 2025 in another article. Methodology For this article, I screened the best-performing healthcare stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).Why Nutex Health Inc (NUTX) is Surging in 2025 A medical professional in scrubs providing care to a patient. Nutex Health Inc. (NASDAQ:NUTX) Number of Hedge Fund Holders In Q4 2024: 6 Nutex Health Inc. (NASDAQ:NUTX) is a physician-led healthcare services company operating micro-hospitals, population health management, and real estate segments across the United States. The stock is up significantly so far in 2025 after the fourth-quarter and full-year 2024 earnings report, released in late March 2025, which showed total revenue nearly doubling to $479.9 million and net income swinging to $52.2 million from a $45.8 million loss the prior year. Adjusted EBITDA jumped over 1,000% to $123.7 million, and the hospital division saw visits rise by 17%. A key driver behind this explosive growth was Nutex Health Inc. (NASDAQ:NUTX)’s strategic shift in mid-2024 to aggressively pursue arbitration under the No Surprises Act for out-of-network claims. This resulted in much higher reimbursement rates per visit and an over 80% success rate in claims. Story Continues The consensus price target of $80 implies 35.24% downside. Nutex Health Inc. (NASDAQ:NUTX) stock is up 289.84% year-to-date. Overall, NUTX ranks 4th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of NUTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUTX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Why Nutex Health Inc. (NUTX) is Surging in 2025
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...